Should Jardiance Be Held During a UTI?
No, you should not routinely hold Jardiance (empagliflozin) when a patient develops a simple urinary tract infection (UTI). Continue the medication while treating the UTI with appropriate antibiotics, but temporarily discontinue it if the patient develops complicated UTI (pyelonephritis, urosepsis) or shows signs of systemic illness with reduced oral intake.
Clinical Approach
For Simple/Uncomplicated UTI (Cystitis)
- Continue Jardiance and treat the UTI with standard antibiotics 1
- The FDA label acknowledges increased UTI incidence (16.6-18.4% in females, 3.2-4.1% in males on empagliflozin vs. 16.6% and 3.2% on placebo respectively), but discontinuation rates were minimal (0.1-0.2%) 1
- Monitor for symptom resolution with antibiotic therapy
Temporarily Hold Jardiance If:
Complicated UTI develops:
- Pyelonephritis (flank pain, fever, systemic symptoms)
- Urosepsis or signs of septic shock
- The FDA specifically warns about urosepsis and pyelonephritis in postmarketing surveillance 1
- Case reports document severe complications including septic shock from Serratia marcescens 2 and emphysematous cystitis 3
Patient has reduced oral intake or increased fluid losses:
- Acute illness, vomiting, diarrhea, or excessive heat exposure
- These conditions increase risk of volume depletion and acute kidney injury 1
- The medication increases urine volume and frequency, enhancing dehydration risk 1
Risk Stratification
Higher Risk Patients (Monitor More Closely):
- History of chronic or recurrent UTIs (these patients are more likely to develop UTIs on SGLT2i) 1
- Female patients (higher baseline UTI risk)
- Uncircumcised males
- Uncontrolled hyperglycemia
- Older adults 4
Important caveat: Recent data suggest that even patients with prior UTI history do not have significantly higher rates of new UTIs after SGLT2i initiation (30.2% vs. 20.4% in UTI-naive patients, p=0.13) 5, so prior UTI history should not be an absolute barrier to continuing therapy.
When to Resume After Holding
- Once complicated infection is treated and resolved
- Patient is hemodynamically stable
- Adequate oral intake restored
- No ongoing signs of systemic infection
Key Clinical Pitfalls to Avoid
Don't automatically discontinue for simple cystitis - this is overly cautious and deprives patients of cardiovascular and renal benefits 4, 6
Don't ignore warning signs of progression - watch for fever, flank pain, nausea/vomiting that could indicate pyelonephritis requiring temporary discontinuation
Don't restart too quickly after complicated UTI - ensure complete resolution and adequate hydration before resuming
Don't forget the cardiovascular benefits - empagliflozin reduces cardiovascular death by 38% and all-cause mortality by 32% in high-risk patients 4, so unnecessary discontinuation has real consequences
The Evidence Context
The FDA label shows UTI rates were only marginally higher with empagliflozin versus placebo, and discontinuation due to UTI was rare (0.1-0.2%) 1. While serious complications like urosepsis and pyelonephritis are documented in postmarketing surveillance 1 and case reports 2, 3, 7, these remain uncommon. Recent mechanistic research even suggests empagliflozin may modulate kidney immune response favorably during infection 8.
The bottom line: Simple UTIs are managed with antibiotics while continuing Jardiance; only complicated infections or systemic illness warrant temporary discontinuation.